GLYCART Biotechnology Appoints William J. Jenkins to Board of Directors
29-Apr-2004 -
Zürich, Switzerland - GLYCART Biotechnology, a privately held
company leveraging a novel technology to enhance the activity of therapeutic
antibodies for the treatment of cancer and autoimmune diseases (GlycoMAb(TM)),
today announced that William J. Jenkins, MA, MSc, MD, FRCP has joined the ...
autoimmune diseases
Ciba
Life Sciences
+5